Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 4;15(15):3969.
doi: 10.3390/cancers15153969.

Current Trends in Chemotherapy in the Treatment of Metastatic Prostate Cancer

Janice Zhao  1 , Brendan J Guercio  1 , Deepak Sahasrabudhe  1
Affiliations
Review

Current Trends in Chemotherapy in the Treatment of Metastatic Prostate Cancer

Janice Zhao et al. Cancers (Basel). .

Abstract

Prostate cancer is the second most common cancer among men. Despite advances in diagnosis and management, prostate cancer led to more than 300,000 deaths globally in 2020. Chemotherapy is a cornerstone of therapy for advanced prostate cancer and can prolong survival of patients with both castration-sensitive and castration-resistant disease. Herein, we present a comprehensive review of the data supporting implementation of chemotherapy in the modern treatment of advanced prostate cancer, with special attention to the use of chemotherapy for aggressive variant prostate cancer (e.g., neuroendocrine prostate cancer) and the combination of chemotherapy with androgen signaling inhibitors. As the field of prostate cancer research continues to rapidly evolve yielding novel agents and treatment modalities, chemotherapy continues to play an essential role in prolonging the survival of patients with advanced and metastatic prostate cancer.

Keywords: cabazitaxel; castration-resistant; castration-sensitive; chemotherapy; docetaxel; mitoxantrone; oncology; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

B.J.G. reports honoraria from Medscape; current or past institutional research funding from Oncocyte, Bristol-Myers Squibb, Genentech, Eli Lilly, Pfizer, and Sanofi; and personal expenses from EMD Serono, Natera, Gilead, Seagen, Exelixis, and Aveo Oncology. J.Z. and D.S. declare no conflicts of interest.

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Rawla P. Epidemiology of Prostate Cancer. World J. Oncol. 2019;10:63–89. doi: 10.14740/wjon1191. - DOI - PMC - PubMed
    1. Wang L., Lu B., He M., Wang Y., Wang Z., Du L. Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. Front. Public Health. 2022;10:811044. doi: 10.3389/fpubh.2022.811044. - DOI - PMC - PubMed
    1. Siegel R.L., Miller D.M., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J. Clin. 2023;73:17–48. doi: 10.3322/caac.21763. - DOI - PubMed
    1. Leslie S.W., Soon-Sutton T.L., Anu R.I.A., Sajjad H., Siref L.E. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2023. Prostate Cancer. - PubMed